Transcend Capital Advisors LLC Buys 188 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Transcend Capital Advisors LLC boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.5% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,586 shares of the medical research company’s stock after acquiring an additional 188 shares during the quarter. Transcend Capital Advisors LLC’s holdings in Thermo Fisher Scientific were worth $4,026,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Strategic Blueprint LLC boosted its holdings in shares of Thermo Fisher Scientific by 7.8% in the 3rd quarter. Strategic Blueprint LLC now owns 1,124 shares of the medical research company’s stock worth $569,000 after purchasing an additional 81 shares in the last quarter. Apeiron RIA LLC boosted its holdings in Thermo Fisher Scientific by 4.8% during the 3rd quarter. Apeiron RIA LLC now owns 671 shares of the medical research company’s stock valued at $340,000 after acquiring an additional 31 shares during the period. First Personal Financial Services lifted its holdings in Thermo Fisher Scientific by 1.9% in the 3rd quarter. First Personal Financial Services now owns 19,621 shares of the medical research company’s stock worth $9,932,000 after buying an additional 359 shares during the period. MCF Advisors LLC lifted its holdings in Thermo Fisher Scientific by 59.7% in the 3rd quarter. MCF Advisors LLC now owns 1,817 shares of the medical research company’s stock worth $920,000 after buying an additional 679 shares during the period. Finally, U.S. Capital Wealth Advisors LLC raised its position in shares of Thermo Fisher Scientific by 2.1% in the 3rd quarter. U.S. Capital Wealth Advisors LLC now owns 8,606 shares of the medical research company’s stock worth $4,356,000 after acquiring an additional 175 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now directly owns 1,207 shares of the company’s stock, valued at $660,192.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Debora L. Spar sold 164 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the sale, the director now directly owns 1,207 shares in the company, valued at $660,192.79. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the sale, the chief executive officer now owns 49,155 shares in the company, valued at $27,311,992.65. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock valued at $28,513,384 over the last ninety days. 0.32% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. JPMorgan Chase & Co. raised their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday. Deutsche Bank Aktiengesellschaft lifted their target price on Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday. Citigroup started coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 target price for the company. Barclays raised their price target on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research note on Thursday. Finally, HSBC raised their price target on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $606.76.

Thermo Fisher Scientific Price Performance

NYSE:TMO traded up $1.87 on Friday, reaching $573.60. 1,438,184 shares of the company’s stock traded hands, compared to its average volume of 1,317,052. The company has a quick ratio of 1.39, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. The stock has a 50-day simple moving average of $573.60 and a 200-day simple moving average of $529.90. The firm has a market cap of $218.95 billion, a PE ratio of 36.79, a P/E/G ratio of 2.41 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. The business had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.54 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a dividend of $0.39 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.